Desvenlafaxine: application withdrawal. Desvenlafaxine: withdrawal of marketing application for depression also.
A welcome move! This psychoactive agent has an unfavourable risk-benefit balance in both hot flushes and depression.
D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003511:Cyclohexanols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy*; D003866:Depressive Disorder / Q000188:drug therapy*; D000069468:Desvenlafaxine Succinate; D005060:Europe; D019584:Hot Flashes / Q000188:drug therapy*; D006801:Humans; D017387:Investigational New Drug Application; D008389:Marketing of Health Services; D014179:Neurotransmitter Uptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017698:Postmenopause; D014481:United States
D000928:Antidepressive Agents; D003511:Cyclohexanols; D014179:Neurotransmitter Uptake Inhibitors; D000069468:Desvenlafaxine Succinate